Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer Supplementary Figure 1

This study sponsored by Eli Lilly and Company. Astra M. Liepa, Zhanglin Lin Cui, Julie K. Beyrer, and Anindya Chatterjee are employees and stockholders at Eli Lilly and Company. Elizabeth L. Hadden is a former employee of DeLisle Associates LTD., and was sub-contracted by Eli Lilly and Company at the time of manuscript development. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The authors would like to thank Karan Sharma from Eli Lilly and Company for providing medical writing and editorial support.